Table 2 Clinical trials for COVID-19 treatment using human placenta MSCs

NCT04390139

Efficacy and safety evaluation of mesenchymal stem cells for the treatment of patients with respiratory distress due to COVID-19

WJ-MSCs

Recruiting

1; 2

-All-cause mortality at day 28.

-Safety of WJ-MSC.

-Need for treatment with rescue medication.

-Ventilator free days.

-Duration of hospitalization.

-Evolution of markers of immune response.

-And 9 more.

Spain

NCT04456361

Use of mesenchymal stem cells in acute respiratory distress syndrome caused by COVID-19

WJ-MSCs

Active, not recruiting

1

-Oxygen saturation.

-Oxygen pressure in inspiration.

-Ground-glass opacity.

-Pneumonia infiltration.

-And 4 more.

Mexico

NCT04313322

Treatment of COVID-19 patients using Wharton’s jelly-mesenchymal stem cells

WJ-MSCs

Recruiting

1

-Clinical outcome.

-CT Scan.

-RT-PCR results.

Jordan

NCT04461925

Treatment of coronavirus COVID-19 pneumonia pathogen SARS-CoV-2) with cryopreserved allogeneic P-MMSCs and UC-MMSCs

P-MMSCs

Recruiting

1; 2

-Changes in length of hospital stay.

-Changes in mortality rate.

-Evaluation of pneumonia improvement.

-Peripheral blood count recovery time.

-And 3 more.

Ukraine

NCT04565665

Cord blood-derived mesenchymal stem cells for the treatment of COVID-19 related acute respiratory distress syndrome

CB-MSCs

Recruiting

1

-Incidence of composite serious adverse events.

-Overall survival rate.

-Determine the treatment effect on clinical parameters, oxygenation and respiratory parameters.

-And 10 more.

USA

NCT04494386

Umbilical cord lining stem cells (ULSC) in patients with COVID-19 ARDS

ULSCs

Recruiting

1; 2

-Incidence of dose limiting toxicity.

-Changes in levels of blood glucose (mg/dL) from baseline.

-Changes in levels of sodium and potassium (mEq/L) from baseline.

-And 9 more.

USA

NCT04573270

Mesenchymal stem cells for the treatment of COVID-19

UC-MSCs

Completed

1

-Survival rates.

-Contraction rates

USA

NCT04288102

Treatment with human umbilical cord-derived mesenchymal stem cells for severe corona virus disease 2019 (COVID-19)

UC-MSCs

Completed

2

-Change in lesion, ground-glass, or consolidation lesion proportion of full lung volume from baseline to day 10, 28, and 90.

-Time to clinical improvement.

-And 5 more.

China

NCT04355728

Use of UC-MSCs for COVID-19 patients

UC-MSCs

Completed

1; 2

-Incidence of pre-specified infusion associated adverse events.

-Incidence of severe adverse events.

-Survival rate after 90 days post first infusion. -Ventilator-free days.

-Change in oxygenation index.

-And 11 more.

USA

NCT04252118

Mesenchymal stem cell treatment for pneumonia patients infected with COVID-19

UC-MSCs

Recruiting

1

-Size of lesion area by

Chest radiograph or CT.

-Time of nucleic acid turning negative.

-CD4+ and CD8+ T cell count.

-And 6 more

China

NCT04416139

Mesenchymal stem cell for acute respiratory distress syndrome due for COVID-19

UC-MSCs

Recruiting

2

-Changes in body temperature.

-General biochemical changes in Leukocytes.

-Functional respiratory change: PaO2/FiO2 ratio.

-And 23 more.

Mexico

NCT04437823

Efficacy of intravenous infusions of stem cells in the treatment of COVID-19 patients

UC-MSCs

Recruiting

2

-Safety and efficacy assessment of infusion associated adverse events.

-Chest radiograph or CT scan.

-COVID-19 QRT-PCR.

-And 3 more.

Pakistan

NCT04333368

Cell therapy using umbilical cord-derived mesenchymal stromal cells in SARS-CoV-2-related ARDS

UC-MSCs

Recruiting

1; 2

-Lung injury score.

-Oxygenation index.

-In-hospital mortality.

-Mortality.

-Ventilator-free days.

-Cumulative use and duration of sedatives.

-And 9 more.

France

NCT04366063

Mesenchymal stem cell therapy for SARS-CoV-2- related acute respiratory distress syndrome

UC-MSCs

Recruiting

2; 3

-Adverse events assessment.

-Blood oxygen saturation.

-Clinical symptoms.

-Respiratory efficacy.

-Biomarker concentrations.

-Intensive care unit-free days.

Republic of Islamic

NCT04339660

Clinical research of human mesenchymal stem cells in the treatment of COVID-19 Pneumonia

UC-MSCs

Recruiting

1; 2

-The immune function.

-Blood oxygen saturation.

-Duration of respiratory symptoms.

-COVID-19 nucleic acid negative time.

-And 4 more.

China

NCT03042143

Repair of acute respiratory distress syndrome by stromal cell administration (REALIST) (COVID-19)

UC-MSCs

Recruiting

1; 2

-Respiratory compliance.

-Oxygenation index.

-Driving pressure.

-Extubation and reintubation.

-Ventilation free days at day 28.

-And 6 more.

UK

NCT04399889

hCT-MSCs for COVID19 ARDS

UC-MSCs

Recruiting

1; 2

-Survival after 28 days after the first dose of MSCs.

-The number of ventilator free days.

-And 8 more.

USA

NCT04269525

Umbilical cord (UC)-derived mesenchymal stem cells (MSCs) Treatment for the 2019-novel coronavirus (nCOV) pneumonia

UC-MSCs

Recruiting

2

-Oxygenation index.

-28 days mortality.

-Hospital stays. 2019-nCoV antibody test.

-2019-nCoV nucleic acid test.

-Improvement of lung imaging examinations.

-And 13 more.

China

NCT04366271

Clinical trial of allogeneic mesenchymal cells from umbilical cord tissue in patients with COVID-19 (MESCEL-COVID19)

UC-MSCs

Recruiting

2

-Mortality from any cause at 28 days.

-Patients alive and without mechanical ventilation on day 14.

-Patients cured at 15 days.

-And 8 more.

Spain

NCT04371601

Safety and effectiveness of mesenchymal stem cells in the treatment of pneumonia of coronavirus disease 2019

UC-MSCs

Active, not recruiting

1

-Changes of oxygenation index.

-Detection of TNF-α, IL-10 levels.

-Immune cell detection.

-And 2 more.

China

ChiCTR2000031430

Clinical study of human umbilical cord mesenchymal stem cells in the treatment of novel coronavirus pneumonia (COVID-19) induced pulmonary fibrosis

UC-MSCs

Recruiting

2

-Coagulation.

-High resolution CT for chest.

-Blood gas analysis.

-Blood routine.

-Cytokine analysis.

-And 16 more.

China